Llagas, Rizelda .
HRN: 21-89-81 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
09/20/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
09/20/2022
09/27/2022
IV
500 Mg
Q8
Prom Msaf
Waiting Final Action
Indication: Empiric Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes